Delcath Systems
DCTH

$8.70

0%

Market Cap: 242M

About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Employees: 76

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

260% more call options, than puts

Call options by funds: $1.19M | Put options by funds: $332K

200% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 2 (+2) [Q1 2024]

41% more capital invested

Capital invested by funds: $28.3M [Q4 2023] → $39.9M (+$11.6M) [Q1 2024]

3.32% more ownership

Funds ownership: 30.9% [Q4 2023] → 34.22% (+3.32%) [Q1 2024]

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

14% less funds holding

Funds holding: 42 [Q4 2023] → 36 (-6) [Q1 2024]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$18

107%

upside

Avg. target

$21

144%

upside

High target

$25

187%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Craig-Hallum Chase Knickerbocker	107%upside $18	Buy Initiated	28 Jun 2024
HC Wainwright & Co. Swayampakula Ramakanth	153%upside $22	Buy Maintained	15 May 2024
Stephens & Co. Sudan Loganathan	187%upside $25	Overweight Initiated	14 May 2024
HC Wainwright & Co. Swayampakula Ramakanth	130%upside $20	Buy Maintained	27 Mar 2024

See Analyst Rankings

Financial journalist opinion

Delcath Systems to Host Second Quarter 2024 Earnings Call

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Monday, August 5, 2024.

Delcath Systems to Host Second Quarter 2024 Earnings Call

Zacks Investment Research

Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?

Have $5-10? 7 Affordable Stocks That Are About to Breakout.

Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower.

Have $5-10? 7 Affordable Stocks That Are About to Breakout.

Zacks Investment Research

Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 197.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. “We are pleased to welcome Dr. Martell to the Delcath Board,” said John Sylvester, Chairman of the Delcath Board of Directors. “Dr. Martell's extensive experience serving both.

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

Zacks Investment Research

Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know

The mean of analysts' price targets for Delcath Systems (DCTH) points to a 201.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know

Zacks Investment Research

What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'

Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'

Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript

Delcath Systems Inc (NASDAQ:DCTH ) Q1 2024 Results Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Officer Gerard Michel - Chief Executive Officer Sandra Pennell - Senior Vice President of Finance Kevin Muir - General Manager, Interventional Oncology Conference Call Participants William Maughan - Canaccord Genuity LLC Marie Thibault - BTIG Yale Jen - Laidlaw & Company Sean Lee - H.C. Wainwright & Co., LLC Operator Good day.

Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y. , May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the first quarter ended March 31, 2024.

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

Delcath Systems to Host First Quarter 2024 Earnings Call

QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2024.

Delcath Systems to Host First Quarter 2024 Earnings Call

See News Rankings